Literature DB >> 11498360

Hypoxic cytotoxic agents: a new approach to cancer chemotherapy.

J. Martin Brown1.   

Abstract

Many of the cells in solid tumors are hypoxic. This makes them resistant to killing by both radiotherapy and most commonly used anticancer drugs. The resistance towards anticancer drugs is because hypoxia induces a non-proliferative state as well as the fact that the hypoxic cells are furthest from the blood vessels in the tumor (and hence the source of drug). However, a new class of drugs - hypoxic cytotoxins can, by killing these hypoxic cells, not only overcome this resistance, but also exploit hypoxia thereby converting it into a therapeutic advantage. The first drug to be tested in the clinic purely for its activity towards hypoxic cells, tirapazamine, is described. Copyright 2000 Harcourt Publishers Ltd.

Entities:  

Year:  2000        PMID: 11498360     DOI: 10.1054/drup.2000.0120

Source DB:  PubMed          Journal:  Drug Resist Updat        ISSN: 1368-7646            Impact factor:   18.500


  4 in total

1.  Low-field magnetic resonance imaging to visualize chronic and cycling hypoxia in tumor-bearing mice.

Authors:  Hironobu Yasui; Shingo Matsumoto; Nallathamby Devasahayam; Jeeva P Munasinghe; Rajani Choudhuri; Keita Saito; Sankaran Subramanian; James B Mitchell; Murali C Krishna
Journal:  Cancer Res       Date:  2010-07-20       Impact factor: 12.701

Review 2.  Improving cancer therapies by targeting the physical and chemical hallmarks of the tumor microenvironment.

Authors:  Jill W Ivey; Mohammad Bonakdar; Akanksha Kanitkar; Rafael V Davalos; Scott S Verbridge
Journal:  Cancer Lett       Date:  2015-12-24       Impact factor: 8.679

3.  Preferential DNA cleavage under anaerobic conditions by a DNA-binding ruthenium dimer.

Authors:  Thamara K Janaratne; Abhishek Yadav; Fiona Ongeri; Frederick M MacDonnell
Journal:  Inorg Chem       Date:  2007-03-28       Impact factor: 5.165

Review 4.  Targeting Tumor Microenvironment by Small-Molecule Inhibitors.

Authors:  Shangwei Zhong; Ji-Hak Jeong; Zhikang Chen; Zihua Chen; Jun-Li Luo
Journal:  Transl Oncol       Date:  2019-11-27       Impact factor: 4.243

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.